RhumbLine Advisers
NYMX

RhumbLine Advisers’s Nymox Pharmaceutical Corp NYMX Stock Holding History

RhumbLine Advisers’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,467
Closed -$68K – 3143
2021
Q1 		$68K Buy
30,467
+100
+0.3% +$264 ﹤0.01% 2965
2020
Q4 		$75K Buy
30,367
+3,833
+14% +$8.47K ﹤0.01% 2996
2020
Q3 		$65K Sell
26,534
-8,305
-24% -$24.2K ﹤0.01% 2936
2020
Q2 		$124K Buy
+34,839
New +$110K ﹤0.01% 2919
2019
Q2 		– Sell
-42,145
Closed -$83K – 3023
2019
Q1 		$83K Sell
42,145
-415
-1% -$880 ﹤0.01% 2884
2018
Q4 		$56K Buy
42,560
+13,180
+45% +$24.1K ﹤0.01% 2936
2018
Q3 		$72K Sell
29,380
-800
-3% -$2.36K ﹤0.01% 2892
2018
Q2 		$101K Buy
30,180
+3,580
+13% +$13.8K ﹤0.01% 2871
2018
Q1 		$113K Buy
26,600
+1,820
+7% +$6.31K ﹤0.01% 2727
2017
Q4 		$82K Sell
24,780
-6,172
-20% -$22.5K ﹤0.01% 2794
2017
Q3 		$118K Buy
30,952
+520
+2% +$1.97K ﹤0.01% 2851
2017
Q2 		$134K Buy
+30,432
New +$125K ﹤0.01% 2859

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TEE
Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

RhumbLine Advisers's NYMX Position: Q2 2021 in Review

RhumbLine Advisers sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2021, closing a stake of 30,467 shares — an estimated $68K sold.

RhumbLine Advisers first reported a position in NYMX in Q2 2017 and held it in 12 quarters. The position peaked at $134K in Q2 2017. 51 funds tracked by Wall St. Rank hold NYMX as of Q2 2021.

  • RhumbLine Advisers reported no remaining Nymox Pharmaceutical Corp position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 30,467 Nymox Pharmaceutical Corp shares in Q2 2021, an estimated $68K.
  • RhumbLine Advisers first reported a position in Nymox Pharmaceutical Corp in Q2 2017 and held it in 12 quarters.
  • RhumbLine Advisers's Nymox Pharmaceutical Corp position peaked at $134K in Q2 2017.
  • 51 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.